{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:56:08Z","timestamp":1782892568716,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Verrica Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13555-021-00576-y","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T02:03:00Z","timestamp":1626832980000},"page":"1623-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug\u2013Device Product Containing Topical Cantharidin (0.7% w\/v) Under Occlusion for the Treatment of Common Warts"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03487549","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Scott","family":"Guenthner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"McFalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Eads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Willson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Olivadoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"3","key":"576_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1525-1470.2003.20318.x","volume":"20","author":"MM Clifton","year":"2003","unstructured":"Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20(3):268\u201371.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"576_CR2","first-page":"1233","volume":"67","author":"DL Stulberg","year":"2003","unstructured":"Stulberg DL, Hutchinson AG. Molluscum contagiosum and warts. Am Fam Physician. 2003;67(6):1233\u201340.","journal-title":"Am Fam Physician"},{"issue":"3","key":"576_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1440-0960.2003.00672.x","volume":"44","author":"A Ciconte","year":"2003","unstructured":"Ciconte A, Campbell J, Tabrizi S, Garland S, Marks R. Warts are not merely blemishes on the skin: a study on the morbidity associated with having viral cutaneous warts. Australas J Dermatol. 2003;44(3):169\u201373.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"576_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1046\/j.1365-2133.2001.04066.x","volume":"144","author":"JC Sterling","year":"2001","unstructured":"Sterling JC, Handfield-Jones S, Hudson PM, British Association of Dermatology. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144(1):4\u201311.","journal-title":"Br J Dermatol"},{"key":"576_CR5","volume":"9","author":"CS Kwok","year":"2012","unstructured":"Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;9:CD001781.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"576_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2133.2011.10218.x","volume":"165","author":"CS Kwok","year":"2011","unstructured":"Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011;165(2):233\u201346.","journal-title":"Br J Dermatol"},{"issue":"5","key":"576_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archderm.1958.01560050014003","volume":"77","author":"WL Epstein","year":"1958","unstructured":"Epstein WL, Kligman AM. Treatment of warts with cantharidin. AMA Arch Derm. 1958;77(5):508\u201311.","journal-title":"AMA Arch Derm"},{"key":"576_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0022-1759(01)00467-7","volume":"257","author":"R Day","year":"2001","unstructured":"Day R, Harbord M, Forbes A, Segal A. Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods. 2001;257:213\u201320.","journal-title":"J Immunol Methods"},{"issue":"2","key":"576_CR9","first-page":"27","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Kircik L. Topical cantharidin in the management of molluscum contagiosum: preliminary assessment of an ether-free, pharmaceutical-grade formulation. J Clin Aesthet Dermatol. 2019;12(2):27\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"key":"576_CR10","first-page":"82","volume":"2","author":"HM Panzer","year":"1961","unstructured":"Panzer HM. Cantharidin\u2014a useful agent in the local treatment of warts. J Germantown Hosp. 1961;2:82\u20136.","journal-title":"J Germantown Hosp"},{"issue":"8","key":"576_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1001\/archderm.1977.01640080136040","volume":"113","author":"EW Rosenberg","year":"1977","unstructured":"Rosenberg EW, Amonette RA, Gardner JH. Cantharidin treatment of warts at home. Arch Dermatol. 1977;113(8):1134.","journal-title":"Arch Dermatol"},{"key":"576_CR12","first-page":"11","volume":"93","author":"JH Epstein","year":"1960","unstructured":"Epstein JH, Epstein WL. Cantharidin treatment of digital and periungual warts. Calif Med. 1960;93:11\u20132.","journal-title":"Calif Med"},{"key":"576_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/09546630802287546","volume":"20","author":"SP Kartal Durmazlar","year":"2009","unstructured":"Kartal Durmazlar SP, Atacan D, Eskioglu F. Cantharidin treatment for recalcitrant facial flat warts: a preliminary study. J Dermatol Treat. 2009;20:114\u20139.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"576_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0002-9394(65)90724-5","volume":"60","author":"RH Bock","year":"1965","unstructured":"Bock RH. Treatment of palpebral warts with cantharon. Am J Ophthalmol. 1965;60(3):529\u201330.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"576_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.7547\/0980445","volume":"98","author":"R Becerro de Bengoa Vallejo","year":"2008","unstructured":"Becerro de Bengoa Vallejo R, Losa Iglesias ME, G\u00f3mez-Mart\u00edn B, S\u00e1nchez G\u00f3mez R, S\u00e1ez CA. Application of cantharidin and podophyllotoxin for the treatment of plantar warts. J Am Podiatr Med Assoc. 2008;98(6):445\u201350.","journal-title":"J Am Podiatr Med Assoc"},{"issue":"1","key":"576_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1525-1470.1984.tb00446.x","volume":"2","author":"RJ Coskey","year":"1984","unstructured":"Coskey RJ. Treatment of plantar warts in children with a salicylic acid-podophyllin-cantharidin product. Pediatr Dermatol. 1984;2(1):71\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"576_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14764172.2017.1326608","volume":"19","author":"S Ghonemy","year":"2017","unstructured":"Ghonemy S. Treatment of recalcitrant plantar warts with long-pulsed Nd:YAG laser versus cantharidin-podophylline resin-salicylic acid. J Cosmet Laser Therapy. 2017;19(6):347\u201352.","journal-title":"J Cosmet Laser Therapy"},{"issue":"7","key":"576_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1468-3083.2011.04186.x","volume":"26","author":"N Ka\u00e7ar","year":"2012","unstructured":"Ka\u00e7ar N, Ta\u015fl\u0131 L, Korkmaz S, Ergin S, Erdo\u011fan B. Cantharidin-podophylotoxin-salicylic acid versus cryotherapy in the treatment of plantar warts: a randomized prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):889\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"576_CR19","first-page":"14","volume":"151","author":"D L\u00f3pez-L\u00f3pez","year":"2015","unstructured":"L\u00f3pez-L\u00f3pez D, Agrasar-Cruz C, Bautista-Casasnovas A, \u00c1lvarez-Castro CJ. Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study. Gac Med Mex. 2015;151(1):14\u20139.","journal-title":"Gac Med Mex"},{"issue":"4","key":"576_CR20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bjd.13310","volume":"171","author":"JC Sterling","year":"2014","unstructured":"Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists\u2019 guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171(4):696\u2013712.","journal-title":"Br J Dermatol"},{"issue":"12","key":"576_CR21","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jamadermatol.2020.3238","volume":"156","author":"LF Eichenfield","year":"2020","unstructured":"Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary drug-device combination product containing cantharidin, 0.7% (w\/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315\u201323.","journal-title":"JAMA Dermatol"},{"key":"576_CR22","doi-asserted-by":"publisher","unstructured":"Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7% (w\/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22:257\u201365. https:\/\/doi.org\/10.1007\/s40257-020-00570-8.","DOI":"10.1007\/s40257-020-00570-8"},{"issue":"20","key":"576_CR23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"3","key":"576_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00128071-200001030-00001","volume":"1","author":"JA Leman","year":"2000","unstructured":"Leman JA, Benton EC. Verrucas. Guidelines for management. Am J Clin Dermatol. 2000;1(3):143\u20139.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T17:58:04Z","timestamp":1633024684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00576-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}